Study title: J Nucl Med Technol. 2007 Mar;35(1):21-6.Reproducibility of a standardized quantitative analysis using fixed regions of interest to differentiate movement disorders on 123I-FP-CIT SPECT. Stokkel MP, Dibbets-Schneider P, Koestering E, Dragoiescu C, Blokland KA. J Nucl Med Technol. 2007 Mar;35(1):21-6.Reproducibility of a standardized quantitative analysis using fixed regions of interest to differentiate movement disorders on 123I-FP-CIT SPECT. Stokkel MP, Dibbets-Schneider P, Koestering E, Dragoiescu C, Blokland KA.
| Type of medicine: Centrally authorised medicines | |||||
| Therapeutic area: Nervous System Diseases | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: ioflupane (123l) | |||||
| ATC code: V09A B 03 | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: CLINICAL | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |